Loading
A phase 3 trial of Teclistamab, Pomalidomide, Bortezomib in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT05572515 by Janssen Research & Development, LLC, with 614 participants enrolled, started 2023-03-29 and due to reach its primary completion in 2025-10-13. Interventions recorded: Teclistamab, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Carfilzomib, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib.
Shares Teclistamab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.